Estados financieros detallados de Marker Therapeutics, Inc. (MRKR): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Resumen del Análisis
Márgenes de los últimos 12 meses: margen bruto -320.8%, margen operativo -8.7%, margen neto -7.1%.
Al precio actual de $1.14, MRKR presenta beneficios negativos (P/E no significativo) y un ROE del -72.42%. La capitalización bursátil es de $19M.
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Ingresos | 0 | $183064 | $205994 | $213194 | $466785 | $1.2M | $3.5M | $3.3M | $6.6M | 0 |
| Coste de Ventas | 0 | $5.3M | $124.0M | $12.8M | $18.9M | $3.2M | $12.0M | $10.4M | $13.5M | 0 |
| Beneficio Bruto | 0 | -$5.1M | -$123.8M | -$12.6M | -$18.4M | -$1.9M | -$8.5M | -$7.1M | -$6.9M | 0 |
| I+D | $3.8M | $5.3M | $124.0M | $12.8M | $18.9M | $27.8M | $12.0M | $10.4M | $13.5M | $11.8M |
| Generales y Administrativos | $4.7M | $6.4M | $24.4M | $10.0M | $10.5M | $9.8M | $11.3M | $7.5M | $4.2M | $4.2M |
| Gastos Operativos | $8.3M | $6.4M | $148.4M | $10.0M | $10.5M | $37.6M | $11.3M | $7.5M | $4.2M | $12.9M |
| Beneficio Operativo | -$8.5M | -$11.5M | -$148.2M | -$22.5M | -$28.9M | -$39.5M | -$19.8M | -$14.6M | -$11.1M | -$12.9M |
| EBITDA | $6.0M | -$11.3M | -$148.0M | -$22.4M | -$27.6M | -$38.7M | -$17.0M | -$11.3M | -$10.7M | -$12.4M |
| Gastos por Intereses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Antes de Impuestos | -$2.5M | -$11.0M | -$148.0M | -$21.4M | -$28.7M | -$41.9M | -$19.8M | -$14.0M | -$10.7M | -$12.2M |
| Impuestos | 0 | 0 | -$214000 | 0 | 0 | 0 | 0 | $3675 | $49953 | -$15156 |
| Beneficio Neto | -$2.5M | -$11.0M | -$148.0M | -$21.4M | -$28.7M | -$41.9M | -$29.9M | -$8.2M | -$10.7M | -$12.2M |
| BPA | $-3.56 | $-11.62 | $-77.50 | $-4.70 | $-6.10 | $-5.47 | $-3.58 | $-1.93 | $-1.19 | $-0.79 |
| BPA Diluido | $-3.31 | $-11.62 | $-77.50 | $-4.70 | $-6.10 | $-5.47 | $-3.58 | $-1.93 | $-1.19 | $-0.79 |
| Acciones en Circulación (Diluidas) | $7.4M | $945348 | $1.9M | $4.6M | $4.7M | $7.7M | $8.4M | $8.8M | $9.0M | $15.3M |
Cuenta de Resultados (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Ingresos | $1.2M | 0 | 0 | 0 |
| Beneficio Bruto | -$1.1M | 0 | -$2.8M | 0 |
| Beneficio Operativo | -$2.1M | -$1.9M | -$4.1M | -$2.6M |
| EBITDA | -$2.0M | -$1.7M | -$3.2M | -$1.8M |
| Beneficio Neto | -$2.0M | -$1.7M | -$3.2M | -$1.8M |
| BPA | $-0.12 | $-0.10 | $-0.16 | $-0.10 |
| BPA Diluido | $-0.12 | $-0.10 | $-0.16 | $-0.10 |
Balance (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Caja y Equivalentes | $7.9M | $5.1M | $61.7M | $43.9M | $21.4M | $42.4M | $11.8M | $15.1M | $19.2M | $16.1M |
| Inversiones a Corto | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cuentas por Cobrar | 0 | 0 | $108177 | $56189 | $1.0M | $237 | $2.4M | $1.0M | $2.3M | $1.4M |
| Inventario | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -$988126 | 0 | 0 |
| Activos Corrientes | $7.9M | $5.2M | $62.0M | $45.5M | $24.4M | $46.0M | $16.6M | $17.1M | $22.0M | $19.1M |
| Inmovilizado Material | 0 | 0 | $148000 | $872702 | $21.2M | $22.2M | $17.8M | 0 | 0 | 0 |
| Fondo de Comercio | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Intangibles | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Totales | $7.9M | $5.2M | $62.1M | $46.4M | $45.6M | $68.1M | $34.4M | $17.1M | $22.0M | $19.1M |
| Cuentas por Pagar | $680000 | $1.0M | $1.6M | $993000 | $2.9M | $5.1M | $1.1M | $961000 | $1.1M | $793727 |
| Deuda a Corto | $5000 | $5000 | 0 | $204132 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pasivos Corrientes | $1.7M | $1.5M | $2.8M | $2.0M | $6.4M | $12.9M | $7.8M | $3.1M | $3.5M | $2.3M |
| Deuda a Largo | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pasivos Totales | $1.7M | $1.5M | $2.8M | $2.3M | $18.3M | $24.1M | $14.8M | $3.1M | $3.5M | $2.3M |
| Reservas | -$145.8M | -$157.4M | -$306.1M | -$327.5M | -$356.2M | -$398.1M | -$428.0M | -$436.3M | -$447.0M | -$459.2M |
| Patrimonio Neto | $6.2M | $3.7M | $59.3M | $44.1M | $27.3M | $44.0M | $19.6M | $14.1M | $18.6M | $16.8M |
| Deuda Total | $5000 | $5000 | 0 | $484379 | $12.3M | $11.9M | $7.6M | 0 | 0 | 0 |
| Deuda Neta | -$7.8M | -$5.1M | -$61.7M | -$43.4M | -$9.1M | -$30.5M | -$4.2M | -$15.1M | -$19.2M | -$16.1M |
| Capital Circulante | $6.2M | $3.7M | $59.2M | $43.5M | $18.0M | $33.1M | $8.8M | $14.1M | $18.6M | $16.8M |
Balance (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Caja y Equivalentes | $17.6M | $16.1M | $14.9M | $11.3M |
| Activos Totales | $21.7M | $19.1M | $17.4M | $14.6M |
| Pasivos Totales | $3.3M | $2.3M | $3.6M | $2.4M |
| Patrimonio Neto | $18.4M | $16.8M | $13.8M | $12.2M |
| Deuda Total | 0 | 0 | 0 | 0 |
Flujo de Caja (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Beneficio Neto | -$2.5M | -$11.0M | -$148.0M | -$21.4M | -$28.7M | -$41.9M | -$19.8M | -$14.0M | -$10.7M | -$12.2M |
| Amortizaciones | 0 | 0 | 0 | $286582 | $1.1M | $3.2M | $3.7M | 0 | 0 | 0 |
| Compensación en Acciones | $1.6M | $2.7M | $16.4M | $5.4M | $5.2M | 0 | $3.3M | $858269 | $245864 | $537540 |
| Cambio en Capital Circulante | $256236 | $302371 | $1.0M | -$2.5M | $2.4M | $5.5M | -$4.8M | $2.8M | -$424873 | -$388000 |
| Flujo de Caja Operativo | -$6.5M | -$8.4M | -$14.5M | -$18.3M | -$20.0M | -$27.3M | -$27.0M | -$16.4M | -$10.9M | -$12.0M |
| Inversiones (CapEx) | 0 | 0 | -$147668 | -$374987 | -$9.3M | -$3.1M | $3 | $1 | $4 | $1 |
| Adquisiciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Recompra de Acciones | 0 | -$310493 | -$71710 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividendos Pagados | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | -$6.5M | -$8.4M | -$14.6M | -$18.7M | -$29.3M | -$30.4M | -$27.0M | -$16.4M | -$10.9M | -$12.0M |
Flujo de Caja (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Flujo de Caja Operativo | -$2.7M | -$1.9M | -$1.4M | -$3.7M |
| Inversiones (CapEx) | -$4 | -$4 | 0 | 0 |
| Flujo de Caja Libre | -$2.7M | -$1.9M | -$1.4M | -$3.7M |
| Dividendos Pagados | 0 | 0 | 0 | 0 |
| Compensación en Acciones | $33279 | $111131 | 0 | $195735 |
Crecimiento y Márgenes (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Crecimiento Ingresos (anual) | | | +12.5% | +3.5% | +118.9% | +166.0% | +183.0% | -5.8% | +99.1% | -100.0% |
| Crecimiento Beneficio Neto (anual) | | -347.3% | -1247.3% | +85.5% | -34.0% | -45.9% | +28.5% | +72.5% | -30.3% | -13.3% |
| Crecimiento BPA (anual) | | -226.4% | -567.0% | +93.9% | -29.8% | +10.3% | +34.6% | +46.1% | +38.3% | +33.6% |
| Cambio en Acciones (anual) | | -87.3% | +101.9% | +138.8% | +3.2% | +62.6% | +9.1% | +5.5% | +1.9% | +70.5% |
| Crecimiento FCF (anual) | | -29.6% | -73.3% | -27.6% | -57.0% | -3.8% | +11.3% | +39.0% | +33.6% | -10.1% |
| Margen Bruto | | -2768.4% | -60095.0% | -5887.4% | -3944.9% | -154.7% | -240.6% | -214.6% | -104.3% | |
| Margen Operativo | | -6271.0% | -71930.3% | -10567.3% | -6188.3% | -3179.3% | -563.3% | -440.4% | -168.7% | |
| Margen EBITDA | | -6171.1% | -71830.2% | -10518.0% | -5919.2% | -3118.0% | -483.5% | -339.9% | -162.1% | |
| Margen Neto | | -5999.0% | -71826.4% | -10050.9% | -6149.7% | -3372.7% | -851.9% | -248.8% | -162.8% | |
| Margen FCF | | -4610.1% | -7101.0% | -8752.3% | -6274.3% | -2449.1% | -767.7% | -496.5% | -165.5% | |
| Tasa Impositiva Efectiva | -0.0% | -0.0% | 0.1% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.5% | 0.1% |
Datos por Acción (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| FCF por Acción | $-0.88 | $-8.93 | $-7.66 | $-4.09 | $-6.23 | $-3.97 | $-3.23 | $-1.87 | $-1.21 | $-0.78 |
| Dividendo por Acción | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acciones en Circulación (Básicas) | $6.9M | $945348 | $1.9M | $4.6M | $4.7M | $7.7M | $8.4M | $8.8M | $9.0M | $15.3M |
Qué mirar en Biotech
La mayoría de biotechs pequeñas pierden dinero. Analizarlas con P/E no tiene sentido — mira caja y pipeline.
- Cash Runway — Meses de caja al ritmo de gasto actual. <18 meses = riesgo de dilución urgente
- Cash burn anual — Ritmo al que queman caja operativa. Comparar con posición de caja para proyectar runway
- Total Debt — Biotech sin ingresos + deuda = receta para bancarrota
- I+D / Capitalización — Cuánto invierten en pipeline vs lo que vale la empresa — indicador de intensidad investigadora
- Market cap / Cash — Si cotiza cerca de su caja, el mercado le da ~0 valor al pipeline — puede ser oportunidad o trampa
Rentabilidad
| Rentabilidad sobre capital | -72.42% |
| Rentabilidad sobre capital invertido | -76.65% |
| Rentabilidad sobre activos | -63.78% |
| Margen bruto | -320.83% |
| Margen operativo | -868.95% |
| Margen neto | -706.23% |
Salud financiera
| Deuda / Patrimonio | 0.00 |
| Ratio corriente | 6.03 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -32.65 |
Ratios Clave (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| P/E | -10.90 | -3.37 | -0.72 | -6.13 | -2.38 | -1.74 | -0.74 | -2.85 | -2.61 | -1.89 |
| P/VC | 43.23 | 10.13 | 1.79 | 2.98 | 2.49 | 1.65 | 1.13 | 3.45 | 1.50 | 1.36 |
| P/V | 0.00 | 202.43 | 514.33 | 615.87 | 146.12 | 58.55 | 6.32 | 14.63 | 4.24 | 0.00 |
| Margen Bruto | 0.0% | -2768.4% | -60095.0% | -5887.4% | -3944.9% | -154.7% | -240.6% | -214.6% | -104.3% | 0.0% |
| Margen Operativo | 0.0% | -6271.0% | -71930.3% | -10567.3% | -6188.3% | -3179.3% | -563.3% | -440.4% | -168.7% | 0.0% |
| Margen Neto | 0.0% | -5999.0% | -71826.4% | -10050.9% | -6149.7% | -3372.7% | -851.9% | -248.8% | -162.8% | 0.0% |